Parkinson's Drugs: Heart Damage Link?
Researchers Raise Concerns About Damage to Heart Valves From 2 Parkinson's Drugs
WebMD News Archive
Jan. 3, 2007 -- Two drugs used in the treatment of Parkinson's disease appear to increase the risk of heart valve disease, according to new research that also raises safety questions about similar-acting drugs.
The drugs pergolide, marketed as Permax, and cabergoline, sold as Dostinex, were associated with heart valve damage in two European studies published in the Jan. 4 issue of the New England Journal of Medicine.
Both drugs are in a class known as ergot-derived dopamine receptor agonists, and both have been linked to heart valve issues in earlier case reports.
"We showed that treatment with either pergolide or cabergoline for more than six months was strongly associated with an increase in valve-related heart disease," Edeltraut Garbe, MD, PhD, tells WebMD. "No increase in risk was seen in patients treated with other dopamine agonists."
Heart Valves and Parkinson's Drugs
Garbe and colleagues from a German research center compared treatment histories among Parkinson's disease patients who did and did not develop heart valve disease.
Heart valves are one-way valves that keep blood flowing in the right direction through your heart. If people have problems with their heart valves then blood may not move the way it should.
The study involved more than 11,000 patients prescribed anti-Parkinson drugs from the U.K. registered in a nationwide database.
The rate of heart valve disease was seven times higher than the rate in a matched comparison group of patients from the group who didn't develop heart valve disease among current pergolide-treated patients -- and five times higher among patients being treated with cabergoline. No increase was seen among current users of other types of dopamine-directed drugs.
Checking for Heart Valve Disease
In a separate study from Italy, researchers performed echocardiograms on Parkinson's patients being treated with either ergot-derived or nonergot-derived dopamine-targeting drugs. An echocardiogram is an ultrasound of the heart which can provide information on the heart's chambers and valves and how well blood is pumping through the heart.
Compared with an age-matched group without Parkinson's disease, patients taking pergolide or cabergoline had significantly more evidence of heart valve disease.